NL8302455A - Farmaceutische samenstelling voor uitwendig gebruik met een verlengde en continue werking op basis van essentiele vetzuren en preparaat op basis van deze samenstelling. - Google Patents

Farmaceutische samenstelling voor uitwendig gebruik met een verlengde en continue werking op basis van essentiele vetzuren en preparaat op basis van deze samenstelling. Download PDF

Info

Publication number: NL8302455A
Authority: NL; Netherlands
Prior art keywords: composition according; acid; esters; group; butyl
Prior art date: 1983-06-29

Application number

NL8302455A

Other languages

English (en)

Dutch (nl)

Original Assignee

Dick P R

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-29

Filing date

1983-07-09

Publication date

1985-01-16

1983-07-09 Application filed by Dick P R filed Critical Dick P R

1985-01-16 Publication of NL8302455A publication Critical patent/NL8302455A/nl

Links

239000000203 mixture Substances 0.000 title claims description 29
235000004626 essential fatty acids Nutrition 0.000 title claims description 6
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
238000002360 preparation method Methods 0.000 title description 9
230000009471 action Effects 0.000 title description 3
150000002148 esters Chemical class 0.000 claims description 15
239000000463 material Substances 0.000 claims description 14
229920003023 plastic Polymers 0.000 claims description 13
239000004033 plastic Substances 0.000 claims description 13
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 10
235000013539 calcium stearate Nutrition 0.000 claims description 10
239000008116 calcium stearate Substances 0.000 claims description 10
239000007787 solid Substances 0.000 claims description 10
241001465754 Metazoa Species 0.000 claims description 9
MBGYSHXGENGTBP-UHFFFAOYSA-N 6-(2-ethylhexoxy)-6-oxohexanoic acid Chemical compound CCCCC(CC)COC(=O)CCCCC(O)=O MBGYSHXGENGTBP-UHFFFAOYSA-N 0.000 claims description 8
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 8
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
239000003381 stabilizer Substances 0.000 claims description 8
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
239000013543 active substance Substances 0.000 claims description 7
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 7
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
235000020778 linoleic acid Nutrition 0.000 claims description 7
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 7
-1 polyethylene Polymers 0.000 claims description 6
229920001577 copolymer Polymers 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
239000004014 plasticizer Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
229920002554 vinyl polymer Polymers 0.000 claims description 5
BJQHLKABXJIVAM-UHFFFAOYSA-N Diethylhexyl phthalate Natural products CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC BJQHLKABXJIVAM-UHFFFAOYSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 4
MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 4
229940087168 alpha tocopherol Drugs 0.000 claims description 4
229940114079 arachidonic acid Drugs 0.000 claims description 4
235000021342 arachidonic acid Nutrition 0.000 claims description 4
QVQLCTNNEUAWMS-UHFFFAOYSA-N barium oxide Chemical compound [Ba]=O QVQLCTNNEUAWMS-UHFFFAOYSA-N 0.000 claims description 4
238000009792 diffusion process Methods 0.000 claims description 4
DJDSLBVSSOQSLW-UHFFFAOYSA-N mono(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(O)=O DJDSLBVSSOQSLW-UHFFFAOYSA-N 0.000 claims description 4
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
239000000123 paper Substances 0.000 claims description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 4
229920001169 thermoplastic Polymers 0.000 claims description 4
239000004416 thermosoftening plastic Substances 0.000 claims description 4
229960000984 tocofersolan Drugs 0.000 claims description 4
239000002076 α-tocopherol Substances 0.000 claims description 4
235000004835 α-tocopherol Nutrition 0.000 claims description 4
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims description 3
239000000853 adhesive Substances 0.000 claims description 3
JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 3
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 3
235000010387 octyl gallate Nutrition 0.000 claims description 3
CZGWDPMDAIPURF-UHFFFAOYSA-N (4,6-dihydrazinyl-1,3,5-triazin-2-yl)hydrazine Chemical compound NNC1=NC(NN)=NC(NN)=N1 CZGWDPMDAIPURF-UHFFFAOYSA-N 0.000 claims description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 2
OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 2
MQIUGAXCHLFZKX-UHFFFAOYSA-N Di-n-octyl phthalate Natural products CCCCCCCCOC(=O)C1=CC=CC=C1C(=O)OCCCCCCCC MQIUGAXCHLFZKX-UHFFFAOYSA-N 0.000 claims description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
239000005977 Ethylene Substances 0.000 claims description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims description 2
239000004743 Polypropylene Substances 0.000 claims description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
YSMRWXYRXBRSND-UHFFFAOYSA-N TOTP Chemical compound CC1=CC=CC=C1OP(=O)(OC=1C(=CC=CC=1)C)OC1=CC=CC=C1C YSMRWXYRXBRSND-UHFFFAOYSA-N 0.000 claims description 2
230000002745 absorbent Effects 0.000 claims description 2
239000002250 absorbent Substances 0.000 claims description 2
239000002253 acid Substances 0.000 claims description 2
239000000654 additive Substances 0.000 claims description 2
239000001361 adipic acid Substances 0.000 claims description 2
235000011037 adipic acid Nutrition 0.000 claims description 2
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
235000006708 antioxidants Nutrition 0.000 claims description 2
125000003118 aryl group Chemical group 0.000 claims description 2
125000000751 azo group Chemical group [*]N=N[*] 0.000 claims description 2
235000019399 azodicarbonamide Nutrition 0.000 claims description 2
VJRITMATACIYAF-UHFFFAOYSA-N benzenesulfonohydrazide Chemical compound NNS(=O)(=O)C1=CC=CC=C1 VJRITMATACIYAF-UHFFFAOYSA-N 0.000 claims description 2
CXKCTMHTOKXKQT-UHFFFAOYSA-N cadmium oxide Inorganic materials [Cd]=O CXKCTMHTOKXKQT-UHFFFAOYSA-N 0.000 claims description 2
CFEAAQFZALKQPA-UHFFFAOYSA-N cadmium(2+);oxygen(2-) Chemical compound [O-2].[Cd+2] CFEAAQFZALKQPA-UHFFFAOYSA-N 0.000 claims description 2
229940090949 docosahexaenoic acid Drugs 0.000 claims description 2
235000020669 docosahexaenoic acid Nutrition 0.000 claims description 2
239000000975 dye Substances 0.000 claims description 2
229960005135 eicosapentaenoic acid Drugs 0.000 claims description 2
235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 2
JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
239000007937 lozenge Substances 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
239000011976 maleic acid Substances 0.000 claims description 2
239000012764 mineral filler Substances 0.000 claims description 2
229910017464 nitrogen compound Inorganic materials 0.000 claims description 2
150000002830 nitrogen compounds Chemical class 0.000 claims description 2
239000000049 pigment Substances 0.000 claims description 2
229920000058 polyacrylate Polymers 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
235000013824 polyphenols Nutrition 0.000 claims description 2
229920001155 polypropylene Polymers 0.000 claims description 2
229920002635 polyurethane Polymers 0.000 claims description 2
239000004814 polyurethane Substances 0.000 claims description 2
229920000131 polyvinylidene Polymers 0.000 claims description 2
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 2
238000007789 sealing Methods 0.000 claims description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
239000011787 zinc oxide Substances 0.000 claims description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims 2
150000001241 acetals Chemical class 0.000 claims 1
235000015112 vegetable and seed oil Nutrition 0.000 claims 1
239000008158 vegetable oil Substances 0.000 claims 1
229920001519 homopolymer Polymers 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 7
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
229920000459 Nitrile rubber Polymers 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
NTXGQCSETZTARF-UHFFFAOYSA-N buta-1,3-diene;prop-2-enenitrile Chemical compound C=CC=C.C=CC#N NTXGQCSETZTARF-UHFFFAOYSA-N 0.000 description 4
WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 4
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
229940094443 oxytocics prostaglandins Drugs 0.000 description 3
239000004800 polyvinyl chloride Substances 0.000 description 3
229920000915 polyvinyl chloride Polymers 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002243 precursor Substances 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000001149 (9Z,12Z)-octadeca-9,12-dienoate Substances 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
229910052788 barium Inorganic materials 0.000 description 2
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 2
229910052793 cadmium Inorganic materials 0.000 description 2
BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000001143 conditioned effect Effects 0.000 description 2
ITNKVODZACVXDS-YATCGRJWSA-N ethyl (4e,7e,10e,13e,16e,19e)-docosa-4,7,10,13,16,19-hexaenoate Chemical compound CCOC(=O)CC\C=C\C\C=C\C\C=C\C\C=C\C\C=C\C\C=C\CC ITNKVODZACVXDS-YATCGRJWSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
229940049918 linoleate Drugs 0.000 description 2
HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
239000000391 magnesium silicate Substances 0.000 description 2
229910052919 magnesium silicate Inorganic materials 0.000 description 2
235000019792 magnesium silicate Nutrition 0.000 description 2
238000000034 method Methods 0.000 description 2
BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
210000000707 wrist Anatomy 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
WTTJVINHCBCLGX-UHFFFAOYSA-N (9trans,12cis)-methyl linoleate Natural products CCCCCC=CCC=CCCCCCCCC(=O)OC WTTJVINHCBCLGX-UHFFFAOYSA-N 0.000 description 1
LNJCGNRKWOHFFV-UHFFFAOYSA-N 3-(2-hydroxyethylsulfanyl)propanenitrile Chemical compound OCCSCCC#N LNJCGNRKWOHFFV-UHFFFAOYSA-N 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
XEEYBQQBJWHFJM-BJUDXGSMSA-N Iron-55 Chemical compound [55Fe] XEEYBQQBJWHFJM-BJUDXGSMSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
PKIXXJPMNDDDOS-UHFFFAOYSA-N Methyl linoleate Natural products CCCCC=CCCC=CCCCCCCCC(=O)OC PKIXXJPMNDDDOS-UHFFFAOYSA-N 0.000 description 1
229920001744 Polyaldehyde Polymers 0.000 description 1
239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002390 adhesive tape Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
SNXPWYFWAZVIAU-UHFFFAOYSA-N arachidonic acid ethyl ester Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)OCC SNXPWYFWAZVIAU-UHFFFAOYSA-N 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
238000005266 casting Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012716 cod liver oil Nutrition 0.000 description 1
239000003026 cod liver oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000001877 deodorizing effect Effects 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
229940066279 eicosapentaenoate Drugs 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000002615 epidermis Anatomy 0.000 description 1
SNXPWYFWAZVIAU-GKFVBPDJSA-N ethyl arachidonate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)OCC SNXPWYFWAZVIAU-GKFVBPDJSA-N 0.000 description 1
FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
229940031016 ethyl linoleate Drugs 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000003925 fat Substances 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
238000001914 filtration Methods 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
238000001192 hot extrusion Methods 0.000 description 1
238000007654 immersion Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
230000000366 juvenile effect Effects 0.000 description 1
FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
239000000944 linseed oil Substances 0.000 description 1
235000021388 linseed oil Nutrition 0.000 description 1
239000006210 lotion Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
239000000574 octyl gallate Substances 0.000 description 1
NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003021 phthalic acid derivatives Chemical class 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
229920002689 polyvinyl acetate Chemical class 0.000 description 1
239000011118 polyvinyl acetate Chemical class 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
206010037844 rash Diseases 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
210000001364 upper extremity Anatomy 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NL8302455A 1983-06-29 1983-07-09 Farmaceutische samenstelling voor uitwendig gebruik met een verlengde en continue werking op basis van essentiele vetzuren en preparaat op basis van deze samenstelling. NL8302455A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR8310735A FR2548021B1 (fr)	1983-06-29	1983-06-29	Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
FR8310735		1983-06-29

Publications (1)

Publication Number	Publication Date
NL8302455A true NL8302455A (nl)	1985-01-16

Family

ID=9290290

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8302455A NL8302455A (nl)	1983-06-29	1983-07-09	Farmaceutische samenstelling voor uitwendig gebruik met een verlengde en continue werking op basis van essentiele vetzuren en preparaat op basis van deze samenstelling.

Country Status (10)

Country	Link
US (1)	US4710383A (fr)
JP (1)	JPS6023315A (fr)
CA (1)	CA1205016A (fr)
CH (1)	CH657988A5 (fr)
DE (1)	DE3325130A1 (fr)
ES (1)	ES8500561A1 (fr)
FR (1)	FR2548021B1 (fr)
GB (1)	GB2142234B (fr)
IT (1)	IT1169745B (fr)
NL (1)	NL8302455A (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1239587A (fr) *	1983-10-24	1988-07-26	David Rubin	Compose d'acides gras pour abaisser les taux de cholesterol et de triglycerides sanguins
GB8420771D0 (en) *	1984-08-15	1984-09-19	Efamol Ltd	Treatment of skin disorders
FR2581310B1 (fr) *	1985-05-02	1988-09-23	Natura Medica Laboratoires	Composition therapeutique comportant de l'acide a-linolenique et un compose susceptible de favoriser le passage de l'acide au travers de la membrane cellulaire et extrait de plantes comprenant l'acide et le compose
GB8527071D0 (en) *	1985-11-04	1985-12-11	Biocompatibles Ltd	Plastics
GB8710780D0 (en) *	1987-05-07	1987-06-10	Scras	Opthalmological application of eicosapentaenoic acid
DE3719097C1 (de) *	1987-06-06	1988-06-09	Fratzer Uwe	Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
JPS647632A (en) *	1987-06-30	1989-01-11	Hitachi Ltd	Inspection device for semiconductor element
JPS646043U (fr) *	1987-06-30	1989-01-13
IT1223290B (it) *	1987-07-27	1990-09-19	Indena Spa	Acidi poliinsaturi ad azione vasocinetica e relative formulazioni farmaceutiche e cosmetiche
US4788064A (en) *	1987-07-31	1988-11-29	Warner-Lambert Company	Transdermal delivery system
US5028431A (en) *	1987-10-29	1991-07-02	Hercon Laboratories Corporation	Article for the delivery to animal tissue of a pharmacologically active agent
JPH04507397A (ja) *	1988-01-14	1992-12-24	フリッツ，アンデルス	湿疹治療用薬剤製造における必須脂肪酸の使用法
US4906475A (en)	1988-02-16	1990-03-06	Paco Pharmaceutical Services	Estradiol transdermal delivery system
AU616502B2 (en) *	1988-04-22	1991-10-31	Medvet Science Pty. Ltd.	Treatment of inflammatory disorders in humans
DE3814047C1 (en) *	1988-04-26	1989-11-16	Fratzer, Antje-Mandy, 6719 Hettenleidelheim, De	Composition for the treatment of multiple sclerosis
GB2218904A (en) *	1988-05-27	1989-11-29	Renafield Limited	Pharmaceutical composition based on high-concentration esters of docosahexaenoic acid
WO1990006120A1 (fr) *	1988-12-01	1990-06-14	Schering Corporation	Compositions d'administration transdermique d'estradiol
US5407957A (en) *	1990-02-13	1995-04-18	Martek Corporation	Production of docosahexaenoic acid by dinoflagellates
CA2082418A1 (fr) *	1990-05-07	1991-12-28	Barry I. Bockow	Methodes et preparations d'huiles stables desodorisees et compositions pharmaceutiques a base de celles-ci
DE4022815A1 (de) *	1990-07-18	1992-01-23	Braun Melsungen Ag	Topische verwendung von (omega)-3-fettsaeuren-zubereitungen fuer hauterkrankungen
DE4042437A1 (de) *	1990-07-18	1992-06-11	Braun Melsungen Ag	Topische verwendung von (omega)-3-fettsaeuren-zubereitungen fuer verbrennungen
DE4133694C2 (de) *	1991-10-11	1993-10-07	Fresenius Ag	Verwendung einer Emulsion mit mehrfach ungesättigten Fettsären zur i.v.-Verabreichung zur Behandlung von Hauterkrankungen
DE4323174C2 (de) *	1993-07-10	1995-09-14	Rhone Poulenc Rorer Gmbh	Pharmazeutische und/oder kosmetische Zubereitung
NL9201438A (nl) *	1992-08-11	1994-03-01	Prospa Bv	Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
DE4238869C2 (de) *	1992-11-18	1994-09-08	Wogepharm Gmbh	Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
US5443844A (en) *	1992-12-03	1995-08-22	Mcdaniel; William R.	Linoleic acid preparations for topical treatment of acne vulgaris
DE4313402A1 (de) *	1993-04-23	1994-10-27	Hexal Pharma Gmbh	Transdermale Wirkstoffzubereitung
DE4330664A1 (de) *	1993-09-10	1995-03-16	Beiersdorf Ag	Verwendungen von Pflanzenölen
DE4432633C2 (de) *	1994-09-14	1997-07-31	Singer Peter Dr Med Priv Doz	Pharmazeutisches Präparat zur lokalen Behandlung von Schuppenflechte, Neurodermitis und Ekzem
DE19503993A1 (de) *	1995-02-08	1996-08-14	Johann Friedrich Dr Med Desaga	Verwendung eines Produktes zur enteralen Versorgung mit Lebensmittelinhaltsstoffen oder Arzneimittelinhaltsstoffen
AU2003299561A1 (en)	2002-11-18	2004-06-15	Vicuron Pharmaceuticals Inc.	Compositions and methods for treating bacterial infections with protein-dalbavancin complexes
US7119061B2 (en)	2002-11-18	2006-10-10	Vicuron Pharmaceuticals, Inc.	Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en)	2002-11-18	2006-04-06	Vicuron Pharmaceuticals Inc.	Dalbavancin compositions for treatment of bacterial infections
ES2452733T3 (es)	2004-05-28	2014-04-02	Abbvie Deutschland Gmbh & Co Kg	Forma de dosificación obtenible a partir de una mezcla pulverulenta que comprende un pigmento inorgánico
BRPI0501708A (pt) *	2005-05-10	2007-05-02	Jean Marc Millet	dispositivo de liberação lenta por processo transdérmico de um medicamento contra o excesso de colesterol e método de produção de um dispositivo transdérmico
GB0808479D0 (en) *	2008-05-09	2008-06-18	Uni I Oslo	Topical compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB951418A (en) *	1960-11-25	1964-03-04	Smith Kline French Lab	Improvements in or relating to a method of preparing high dosage sustained release tablet and product of this method
BE640616A (fr) *	1962-12-19
US3487138A (en) *	1966-11-23	1969-12-30	Merck & Co Inc	Process for preparing a delayed release medicinal tablet
US3574826A (en) *	1968-02-27	1971-04-13	Nat Patent Dev Corp	Hydrophilic polymers having vitamins absorbed therein
FR1605150A (fr) *	1968-12-31	1973-03-16
US3854480A (en) *	1969-04-01	1974-12-17	Alza Corp	Drug-delivery system
US3797494A (en) *	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
GB1476624A (en) *	1973-05-30	1977-06-16	Cepbepe	Tranquiliser medicaments
US4150109A (en) *	1974-05-07	1979-04-17	Dick Pierre R G	Devices for protecting animals from ectoparasites
GB1580444A (en) *	1976-11-04	1980-12-03	Bio Oil Res	Pharmaceutical compositions
DE2755224A1 (de) *	1976-12-15	1978-07-13	Procter & Gamble	Schmerzen und entzuendungen linderndes mittel zur oertlichen anwendung
US4201211A (en) *	1977-07-12	1980-05-06	Alza Corporation	Therapeutic system for administering clonidine transdermally
AU527784B2 (en) *	1978-05-26	1983-03-24	Bang, Hans Olaf Dr.	Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
US4291015A (en) *	1979-08-14	1981-09-22	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing a vasodilator
DE2942021A1 (de) *	1979-10-17	1981-04-30	Bristol Myers Co	Dermatologisches mittel
FR2474310A1 (fr) *	1980-01-25	1981-07-31	Oreal	Solution stable a l'oxydation de vitamine f et d'huile de jojoba et compositions cosmetiques la contenant
DE3152174A1 (de) *	1980-06-27	1982-08-12	Nippon Oils & Fats Co Ltd	Thrombosis-prophylatic and curing agent
CA1163559A (fr) *	1980-07-09	1984-03-13	Alec D. Keith	Matrice polymerique pour l'administration de medicaments par diffusion
DE3039881A1 (de) *	1980-10-22	1982-05-27	Bayer Ag, 5090 Leverkusen	Ektroparasitizidhaltige halsbaender fuer haustiere
DE3039882A1 (de) *	1980-10-22	1982-05-27	Bayer Ag, 5090 Leverkusen	Ektoparasitizidhaltige polyurethane

1983
- 1983-06-29 FR FR8310735A patent/FR2548021B1/fr not_active Expired
- 1983-07-05 CH CH3689/83A patent/CH657988A5/fr not_active IP Right Cessation
- 1983-07-08 GB GB08318564A patent/GB2142234B/en not_active Expired
- 1983-07-08 US US06/511,941 patent/US4710383A/en not_active Expired - Fee Related
- 1983-07-09 NL NL8302455A patent/NL8302455A/nl not_active Application Discontinuation
- 1983-07-11 CA CA000432197A patent/CA1205016A/fr not_active Expired
- 1983-07-11 ES ES524032A patent/ES8500561A1/es not_active Expired
- 1983-07-12 DE DE19833325130 patent/DE3325130A1/de not_active Ceased
- 1983-07-12 IT IT22012/83A patent/IT1169745B/it active
1984
- 1984-06-05 JP JP59115349A patent/JPS6023315A/ja active Pending

Also Published As

Publication number	Publication date
ES524032A0 (es)	1984-11-01
CA1205016A (fr)	1986-05-27
DE3325130A1 (de)	1985-01-03
GB2142234B (en)	1987-07-08
GB8318564D0 (en)	1983-08-10
FR2548021A1 (fr)	1985-01-04
US4710383A (en)	1987-12-01
JPS6023315A (ja)	1985-02-05
GB2142234A (en)	1985-01-16
IT1169745B (it)	1987-06-03
FR2548021B1 (fr)	1986-02-28
IT8322012A0 (it)	1983-07-12
CH657988A5 (fr)	1986-10-15
ES8500561A1 (es)	1984-11-01

Legal Events

Date	Code	Title	Description
1988-03-01	BV	The patent application has lapsed

Publication	Publication Date	Title
NL8302455A (nl)	1985-01-16	Farmaceutische samenstelling voor uitwendig gebruik met een verlengde en continue werking op basis van essentiele vetzuren en preparaat op basis van deze samenstelling.
US5028431A (en)	1991-07-02	Article for the delivery to animal tissue of a pharmacologically active agent
AU2011235597B2 (en)	2015-07-16	Transdermal delivery patch
DE3843239C1 (fr)	1990-02-22
EP0314528B1 (fr)	1992-12-16	Articles pour la libération contrôlée et pour l'administration de substances à des tissus animaux
HU206972B (en)	1993-03-01	Process for producing trnasdermal pharmaceutical composition comprising tulobuterol
JP2638635B2 (ja)	1997-08-06	経皮吸収製剤
FR2698787A1 (fr)	1994-06-10	Patches médicinaux pour administration par voie percutanée.
WO2001085156A1 (fr)	2001-11-15	Compositions dermiques ayant la coenzyme q comme principe actif
HUT73441A (en)	1996-07-29	Transdermal therapeutic compositions and process for producing them
JPH05186324A (ja)	1993-07-27	美白化粧料
DE19906977C1 (de)	2000-06-15	Desoxypeganin-TTS und seine Verwendung
KR20060133900A (ko)	2006-12-27	니코틴 경피 전달 시스템
JPH0867621A (ja)	1996-03-12	グリコサミノグリカン産生促進作用を有する皮膚活性化剤
CH674930A5 (fr)	1990-08-15
EP2135905A2 (fr)	2009-12-23	Emplâtre et procédé de fabrication de celui-ci
JP7269855B2 (ja)	2023-05-09	ジェルシートマスク
JP2020518553A (ja)	2020-06-25	ニコチン含有透明経皮吸収治療システム
WO2001089468A1 (fr)	2001-11-29	Utilisation d'aryloximes pour assurer la prophylaxie et/ou le traitement de la formation d'erytheme et/ou de reactions inflammatoires de la peau
JP3285617B2 (ja)	2002-05-27	貼付剤
DE10341317B4 (de)	2008-10-23	Transdermales therapeutisches System (TTS) zur Verabreichung von Ergolinverbindungen ausgenommen Pergolid
CZ2004316A3 (cs)	2004-10-13	Náplast
FR2783423A1 (fr)	2000-03-24	Systeme de delivrance d'actif comprenant, sur une structure en film, une composition a base d'un derive d'acide salicylique, et ses utilisations
Andrie et al.	2022	Accelerated Stability Test of Snakehead Fish Extract (Channa striata) and Kelulut Honey (Heterotrigona itama) Ointment Combination with BHT as an Antioxidant
DE1266448B (de)	1968-04-18	Praeparat zum Entfernen lebloser verhornter Hautschichten